- Home
- AXIA vs UTHR Comparison
AXIA vs UTHR Comparison
Compare AXIA & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AXIA | UTHR |
|---|---|---|
| Founded | 1962 | 1996 |
| Country | Brazil | United States |
| Employees | 7168 | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.3B | 22.5B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | AXIA | UTHR |
|---|---|---|
| Price | $10.47 | $520.71 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $567.57 |
| AVG Volume (30 Days) | ★ 2.0M | 352.9K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.68% | N/A |
| EPS Growth | N/A | ★ 13.07 |
| EPS | N/A | ★ 5.82 |
| Revenue | N/A | ★ $1,483,300,000.00 |
| Revenue This Year | $15.92 | $6.39 |
| Revenue Next Year | $7.32 | $14.18 |
| P/E Ratio | ★ N/A | $90.09 |
| Revenue Growth | N/A | ★ 2.38 |
| 52 Week Low | $8.78 | $287.65 |
| 52 Week High | $13.54 | $609.35 |
Technical Indicators
Market Signals| Indicator | AXIA | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 56.72 | 36.10 |
| Support Level | $10.52 | $464.92 |
| Resistance Level | $10.82 | $542.66 |
| Average True Range (ATR) | 0.22 | 11.79 |
| MACD | 0.07 | -0.93 |
| Stochastic Oscillator | 84.29 | 7.63 |
Price Performance
Historical ComparisonAbout AXIA AXIA Energia American
Axia Energia is engaged in the generation, transmission, and commercialization of electricity in Brazil. The company operates a portfolio of wind, thermal, hydro, and nuclear power plants located throughout the country.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.